Zepbound (tirzepatide) - Eli Lilly
Perspectives on Newer Antiobesity Drugs (Semaglutide and Tirzepatide) among Healthcare Professionals Treating Obesity in South Asia: A Cross-sectional Survey. (PubMed, J Assoc Physicians India) - Oct 24, 2026 - "Biosimilars could enhance equity, but require robust data and regulation. Targeted education, reimbursement policies, and region-specific evidence are essential to optimize AOM integration in obesity management." 
Journal • Genetic Disorders • Metabolic Disorders • Obesity
http://www.ncbi.nlm.nih.gov/pubmed/42902646
 
Abm Kamrul-Hasan; Aswin Pankaj; Dina Shreshtha; Khushboo Agarwal; Lakshmi Nagendra; Musarrat Riaz; Nitin Kapoor; Rucha Mehta; Sambit Das; Sanjay Kalra; Saptarshi Bhattacharya; Shehla Sheikh; Sourabh Sharma
 
Oct 24, 2026
 
Prev Next